Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial (RESOLVE-CKD)

30 ottobre 2026 aggiornato da: Jing Chen, University of Texas Southwestern Medical Center

REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)

This pilot randomized, open-label, outcome blinded clinical trial is to evaluate the preliminary effects of low-dose Colchicine (LoDoCo) on coronary artery calcification (CAC) progression in adults with chronic kidney disease (CKD) and existing coronary artery calcification. Sixty participants will be randomized 1:1 to received LoDoCo plus usual care or usual care lone and followed for 24 months.

The primary objective is to evaluate the effect of LoDoCo on CAC progression measured by ECG-gates noncontrast cardiac computed tomography (CT). Exploratory outcomes include valvular calcification, bone mineral density, inflammatory, vascular, and miner-bone biomarkers, cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures, kidney biomarkers, and participant-reported measures of treatment acceptability, adherence, and adverse effects.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The investigators will conduct a randomized, open-label, outcome-blinded, clinical trial in 60 adults with chronic kidney disease (CKD) and existing coronary artery calcification (CAC) Agatston scores of ≥100-1000. Participants will be randomized 1:1 to receive low-dose Colchicine (LoDoCo) plus usual care or usual care alone for 24 months.

The primary objective is to evaluate the effect of LoDoCo on CAC progression over 24 months. CAC will be assessed by ECG-gated noncontrast cardiac computed tomography (CT). Outcomes will include Agatston score and calcium volume. The study will estimate variance, baseline-to-follow-up correlations, and other parameters needed to inform future sample size, treatment duration, and endpoint selection.

Exploratory objectives include evaluating the effects of LoDoCo on aortic valve and mitral annular calcification, CT-derived vertebral bone mineral density, inflammatory biomarkers, vascular calcification biomarkers, and miner-bone metabolism biomarkers. Additional exploratory analyses will examine cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures including ankle-brachial index (ABI) and toe-brachial index (TBI), and kidney outcomes including albumin-creatine ratio (uACR) and estimated glomerular filtration rate (eGFR).

Participant experience with LoDoCo will also be evaluated through assessment of treatment acceptability, adherence, adverse effects, and barriers and facilitators to study participation and retention.

Participants will be followed at baseline, 6 months, 12 months, 18 months, and 24 months for data collection. Participants assigned to the intervention group will undergo additional safety monitoring, including laboratory assessments, throughout the study period.

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 30 anni a 69 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Men and women aged 30-<70 years of all race/ethnicity groups
  • Chronic kidney disease (CKD) stage 3 (estimated glomerular filtration rate (eGFR) 30 to <60 ml/min/1.73m2) or eGFR ≥60 and Urine albumin-to-creatinine ratio (uACR) ≥ 30 mg/g
  • Cardiac artery calcification (CAC) Agatston score ≥100-1000
  • Ability to provide informed consent.

Exclusion Criteria:

  • Current Colchicine therapy
  • Hepatic disease
  • Established peripheral arterial disease (PAD) defined by self-report or ICD-10 codes
  • Congestive heart failure classified as New York Heart Association (NYHA) Functional class III or IV
  • Uncontrolled atrial fibrillation with resting heart rate > 100 beats/min
  • Dementia defined by self-report or ICD-10 codes (F01-F03)
  • Alzheimer's disease defined by self-report or ICD-10 codes (G30)
  • Any clinically active diagnosed infection requiring systemic antimicrobial therapy, positive microbiologic evidence of infection, or infection-related hospitalization within 30 days prior to study enrollment.
  • Immunosuppression, including the use of immunosuppressive medications
  • Current use of chemotherapy drugs or active cancer
  • Pregnancy/breastfeeding
  • Hospitalized within the past 6 months
  • Allergic/intolerance to colchicine
  • Use of P-glycoprotein (p-gp) inhibitor (such as Verapamil, Quinidine, Amiodarone, Ritonavir, Lopinavir/ritonavir, Saquinavir, Nelfinavir)
  • Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Clarithromycin, Erythromycin)
  • Human immunodeficiency virus (HIV) infection
  • Gout attack ≥ 1 time per year
  • Severe anemia (hemoglobin < 8 g/dl for women and < 9 g/dl for men)
  • eGFR <30 ml/min/1.73m2
  • White blood cell count (WBC) <3.0 x10^9/L
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x Upper Limit of Normal (ULN)
  • Total bilirubin >2 x ULN
  • Glucose >300mg/dL
  • Uses recreational drugs
  • Participant in other conflict clinical trial
  • Unable to complete the study measurements
  • Unable to undergo to computed tomography (CT)
  • Unsafe to participate in this study per investigator's judgement
  • Unable to read and speak English or Spanish

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Low-Dose Colchicine (LoDoCo)

Participants will receive low-dose Colchicine (LoDoCo) in addition to usual care.

Intervention group will receive LoDoCo (Colchicine 0.5mg), oral, once daily.

Altri nomi:
  • LoDoCo

Participants will receive usual care according to standard clinical practice and treating physician discretion.

Comparatore attivo: Usual Care

Participants will receive usual care alone.

Participants will receive usual care according to standard clinical practice and treating physician discretion.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Coronary Artery Calcification Agatston Scores
Lasso di tempo: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Coronary artery calcification will be quantified using the Coronary Artery Calcium (CAC) Agatston Score. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Change in Coronary Artery Calcification Volume Scores
Lasso di tempo: Baseline, 12 months, 24 months

Change in Coronary Artery Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Exploratory: Change in Aortic Valve Calcification Agatston Scores
Lasso di tempo: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Aortic valve calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the aortic valve. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Aortic Valve Calcification Volume Scores
Lasso di tempo: Baseline, 12 months, 24 months

Change in Aortic Valve Calcification volume (mm3) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months
Exploratory: Change in Mitral Annular Calcification Agatston Scores
Lasso di tempo: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Mitral annular calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the mitral valve annulus. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Mitral Annular Calcification Volume Scores
Lasso di tempo: Baseline, 12 months, 24 months

Change in Mitral Annular Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months
Exploratory: Change in Vertebral Bone Mineral Density (BMD)
Lasso di tempo: Baseline, 12 months, 24 months

Change in vertebral BMD (mg/cm³) will be measured from ECG-gated non-contrast computer tomography (CT) using validated CT-based densitometry methods. BMD will be quantified within the vertebral bodies. Vertebral MBD values range from <80mg/cm³ (very low), 80-120mg/cm³ (low), and >120 mg/cm³ (normal). Lower TBI values are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in C-Reactive Protein (CRP) Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating CRP (mg/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-1 beta (IL-1β) Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating IL-1β levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-6 (IL-6) Levels
Lasso di tempo: Baseline, 12 months, 18 months

Circulating IL-6 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 18 months
Exploratory: Change in Interleukin-18 (IL-18) Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating IL-18 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Tumor Necrosis Factor alpha
Lasso di tempo: Baseline, 12 months, 24 months

Circulating TNF-a levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-17 (IL-17) Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating IL-17 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Monocyte Chemoattractant Protein-1 (MCP-1) levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating MCP-1 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Klotho Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating klotho levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Fetuin A Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating fetuin A levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Osteopontin Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating osteopontin levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-2 (BMP-2) Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating BMP-2 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-4 (BMP-4) Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating BMP-4 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-7 (BMP-7) Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating BMP-7 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Phosphate levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating serum phosphate levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Calcium Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating serum calcium levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Parathyroid Hormone (PTH) levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating PTH levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone-Specific Alkaline Phosphatase (BSAP) Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating serum BSAP levels (ug/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Fibroblast Growth Factor 23 (FGF23) Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating FGF23 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Wnt Inhibitory Factor-1 Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating Wnt Inhibitory Factor-1 (pg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Intact N-Terminal Propeptide of Type I Procollagen (P1NP) Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating P1NP levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Sclerostin Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating sclerostin levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Tartrate-Resistant Acid Phosphatase 5b (TRAP-5b) Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating TRAP-5b levels (U/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in National Institutes of Health (NIH) Toolbox Fluid Cognition Composite Standard Score
Lasso di tempo: Baseline, 12 months, 24 months

The NIH Toolbox Fluid Cognition Composite score assesses cognitive functions involved in processing and responding to new information, including attention, executive function, episodic memory, processing speed, and working memory. The age-adjusted Fluid Cognition Composite Standard Score is derived from participant performance on NIH Toolbox cognitive assessments and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Scores of 70 or lower indicate significant impairment, scores around 85 are below average, scores around 100 are average, scores around 115 are above average, and scores around 130 are superior. Higher scores indicate better cognitive performance.

Baseline, 12 months, 24 months
Exploratory: Change in Executive Function
Lasso di tempo: Baseline, 12 months, 24 months

Executive function will be assessed using the NIH Toolbox Dimensional Change Card Sort Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better executive functioning.

Baseline, 12 months, 24 months
Exploratory: Change in Attention/Inhibitory Control
Lasso di tempo: Baseline, 12 months, 24 months

Attention and inhibitory control will be assessed using the NIH Toolbox Flanker Inhibitory Control Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better attention and inhibitory control.

Baseline, 12 months, 24 months
Exploratory: Change in Processing Speed
Lasso di tempo: Baseline, 12 months, 24 months

Processing speed will be assessed using the NIH Toolbox Pattern Comparison Processing Speed test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better processing speed.

Baseline, 12 months, 24 months
Exploratory: Change in Working Memory
Lasso di tempo: Baseline, 12 months, 24 months

Working memory will be assessed using the NIH Toolbox List Sorting Working Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better working memory.

Baseline, 12 months, 24 months
Exploratory: Change in Episodic Memory
Lasso di tempo: Baseline, 12 months, 24 months

Episodic memory will be assessed using the NIH Toolbox Picture Sequence Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better episodic memory.

Baseline, 12 months, 24 months
Exploratory: Change in Language/Vocabulary
Lasso di tempo: Baseline, 12 months, 24 months

Language/Vocabulary will be assessed using the NIH Toolbox Picture Vocabulary Test and Oral Reading Recognition tests. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better language ability.

Baseline, 12 months, 24 months
Exploratory: Change in Southwestern Assessment of Processing Speed (SWAPS) Score
Lasso di tempo: Baseline, 12 months, 24 months

The SWAPS will be used to assess processing speed. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better processing speed performance.

Baseline, 12 months, 24 months
Exploratory: Change in Texas Card Sorting Test (TCST) Score
Lasso di tempo: Baseline, 12 months, 24 months

The TCST will be used to assess executive functioning, including cognitive flexibility and concept formation. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better executive functioning.

Baseline, 12 months, 24 months
Exploratory: Change in Phosphorylated tau 217 (p-tau217) levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating p-tau217 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Amyloid-beta 42/40 ratio (Aβ42/40) Levels
Lasso di tempo: Baseline, 12 months, 24 months

Circulating Aβ42 and Aβ40 levels (pg/mL) will be measured using standard clinical laboratory assays and the Aβ42/40 ratio calculated from these measurements and reported as a unitless ratio.

Baseline, 12 months, 24 months
Exploratory: Change in Ankle-Brachial Index (ABI)
Lasso di tempo: Baseline, 12 months, 24 months

ABI will be measured using semi-automated validated device (simpleABI-600CL). ABI values range from ≤0.90 (Peripheral artery disease), 0.91-0.99 (borderline), 1.00-1.40 (normal).ABI values >1.40 indicate non-compressible arteries, suggestive of arterial stiffness or medial calcification. Both ABI values ≤0.90 and >1.40 are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Toe-Brachial Index (TBI)
Lasso di tempo: Baseline, 12 months, 24 months

TBI will be measured using semi-automated validated device (simpleABI-600CL). TBI values range from ≥0.70 (normal), 0.64-0.69 (borderline), and <0.40-0.50 (severe distal arterial disease/critical ischemia range). TBI values <0.70 is a commonly used threshold suggestive of peripheral artery disease. Lower TBI values are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Percentage of Participants with Ankle-Brachial Index (ABI) ≤0.9 or >1.4
Lasso di tempo: Baseline, 12 months, 24 months

ABI will be measured using semi-automated validated device (simpleABI-600CL). The percentage (%) of participants with an ABI ≤0.9, indicative of peripheral arterial disease, or an ABI >1.4, indicative of non-compressible arteries suggestive of arterial stiffness or medial calcification will be determined. Higher percentages indicate a greater proportion of participants with abnormal ABI findings.

Baseline, 12 months, 24 months
Exploratory: Change in Urine Albumin-to-Creatine Ratio (uACR)
Lasso di tempo: Baseline, 12 months, 24 months

Circulating urinary albumin and creatine levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Estimated Glomerular Filtration Rate (eGFR)
Lasso di tempo: Baseline, 12 months, 24 months

eGFR values (mL/min/1.73m2) will be calculated using the NKF-ASN CKD-Epi refit formula.

Baseline, 12 months, 24 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Jing Chen, MD, University of Texas

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

30 ottobre 2026

Completamento primario (Stimato)

1 maggio 2029

Completamento dello studio (Stimato)

1 maggio 2029

Date di iscrizione allo studio

Primo inviato

11 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 giugno 2026

Primo Inserito (Effettivo)

17 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

4 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • STU20260896
  • 99077 (Altro identificatore: UT Southwestern Medical Center)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

IRB approval is required before sharing IPD.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .